Some previously published studies have already established a poorer prognosis in YA breast cancer patients as independent from other clinicopathological factors, such as tumour size, nodal status, histological grade, and hormone receptor status [8, 18, 19]. This evidence concerns the gene NR4A1 and breast carcinoma.